Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients with select FGFR alterations.
Phase 1b/2 NORSE Study @MDAndersonNews
Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients with select FGFR alterations.